MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
Location: Zug | Duration: 10–12 weeks | Summer 2026
This is an excellent and rare opportunity to gain experience at a dynamic biotech company and contribute to their exciting journey of global commercialization and pipeline expansion.
We are looking for an energetic, structured and analytical individual to join our International Commercial Operations Team based in Zug, Switzerland. During this summer you will support the evaluation and forecasting of late-stage pipeline products for our international markets. As an intern you will play a key role in the development of a next-generation Excel-based forecasting model in a disease area that is new to Mirum and characterized by distinct epidemiological and market dynamics.
The primary focus of the internship will be the designing and building of a robust, scalable, and assumption-driven forecasting model that integrates into Mirum’s existing international forecasting framework. The model will incorporate disease specific epidemiology, prevalence, diagnosis, and treatment dynamics relevant to the pipeline product.
This project will directly inform long-term strategic planning, geographic prioritization, and commercial readiness for the pipeline assets. In this role, you collaborate cross-functionally with Commercial, Market Access, Medical, Regulatory, Finance, Clinical and Business Development teams to align key inputs and assumptions.
JOB FUNCTIONS/RESPONSIBILITIES
QUALIFICATIONS
Education/Experience
PREFERRED QUALIFICATIONS
Application needs to include a CV and a motivation letter answering these questions:
This is a unique opportunity to contribute meaningfully to an expansion strategy with high impact potential. You’ll be expected to roll up your sleeves, bring structure to ambiguity, and drive insights that shape future decisions.
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.